Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Theakine Derma
- Development stage
- Preclinical
- Lead developer
- Adamas Biotech
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Theakine Derma is a nutraceutical product under development by Adamas Biotech, an Italian company specializing in standardized green tea extracts (GTEs). Formulated with green tea catechins, it is intended for dermatological applications, specifically targeting the management of burns, wounds, and erythema. The product leverages the antioxidant and anti-inflammatory properties of green tea polyphenols, such as epigallocatechin gallate (EGCG), to support the skin's natural healing process and reduce inflammatory responses like redness. As of early 2024, the product is in the preclinical development stage.
- Brand names
- Theakine Derma
- Other names
- Theakine® Derma
Beyond the preview
Go deeper on Theakine Derma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Theakine Derma.